Exploring Predictors of Treatment Response to GLP-1 Receptor Agonists for Smoking Cessation
Nicotine and Tobacco Research · 23.06.2025 · 27 (7) · 1294-1300
DOI: 10.1093/ntr/ntaf005 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Nicotine and Tobacco Research, online erschienen am 09.01.2025. Verfasst von Luba Yammine und 6 weiteren Autor:innen. Beteiligte Einrichtung: Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston (UTHealth), McGovern Me…. Hauptthemen laut MEDLINE: Exenatide, Smoking Cessation, Glucagon-Like Peptide-1 Receptor Agonists, Peptides. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: PARTNERS Research Awards (LY), UTHealth Center for Clinical and Translational Sciences, CTSA Scholar Award (LY).
Abstract (Originalsprache)
Introduction
Understanding predictors of smoking cessation medication efficacy facilitates the ability to enhance treatment effectiveness. In our pilot trial, exenatide, a glucagon-like peptide-1 receptor agonist, adjunct to nicotine patch improved smoking abstinence compared to nicotine patch alone. This secondary analysis explores potential baseline characteristics associated with differential treatment response to exenatide. Aims and Methods The parent trial randomized (1:1) 84 smokers with prediabetes and/or overweight to once-weekly placebo or exenatide, 2 mg, subcutaneously. All participants received nicotine patch (21 mg) and brief smoking cessation counseling, with biologically confirmed 7-day point prevalence abstinence at week 6 (end-of-treatment) deemed the primary outcome. Bayesian generalized linear modeling explored differential response to treatment as a function of baseline patient characteristics, including demographic, psychosocial, clinical, smoking-related, and genetic factors. Posterior probability (PP) ≥ 75% that an effect exists was taken as a minimum threshold of evidence in favor of model effects.
Results
Exenatide showed stronger benefit versus placebo in participants who smoked >20 cigarettes per day (PP = 81.7%) and in those without prediabetes (PP = 76.0%) or obesity (PP = 94.4%). Exenatide’s efficacy was observed only in individuals with no/minimal depression symptoms but not in those with symptoms (PP = 91.2%). Finally, exenatide was more efficacious than placebo only in those with the CHRNA rs16969968 GG genotype (PP = 88.6%).
Conclusions
The effect of exenatide on abstinence may be moderated by the number of cigarettes smoked daily, metabolic, psychological, and genetic factors. Larger prospective investigations are needed to confirm and extend these findings.
Implications
Understanding predictors of smoking cessation medication efficacy enhances the ability to improve treatment effectiveness. In our pilot trial, extended-release exenatide, a GLP-1 receptor agonist, adjunct to nicotine patch, improved smoking abstinence in smokers with prediabetes and/or overweight. The current post-hoc analysis found that the effect of exenatide on smoking abstinence may be moderated by the number of cigarettes smoked daily, metabolic, psychological, and genetic factors. Larger investigations are needed to confirm and extend these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston (UTHealth), McGovern Medical School, Houston, TX, USA.
- Department of Pediatrics, Center for Clinical Research and Evidence-Based Medicine, UTHealth, McGovern Medical School, Houston, TX, USA.
- Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA.
- Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX, USA.
ORCID-Profile: Luba Yammine, Constanza de Dios, Robert Suchting, David A Nielsen
Förderung
- PARTNERS Research Awards (LY)
- UTHealth Center for Clinical and Translational Sciences
- CTSA Scholar Award (LY)
- Quinn Oncology Research Award (LY)
Zitieren
APA
Yammine, L., de Dios, C., Suchting, R., Green, C. E., Nielsen, D. A., Walss-Bass, C., & Schmitz, J. M. (2025). Exploring Predictors of Treatment Response to GLP-1 Receptor Agonists for Smoking Cessation. Nicotine and Tobacco Research, 27(7), 1294-1300. https://doi.org/10.1093/ntr/ntaf005
Vancouver
Yammine L, de Dios C, Suchting R, Green CE, Nielsen DA, Walss-Bass C, et al. Exploring Predictors of Treatment Response to GLP-1 Receptor Agonists for Smoking Cessation. Nicotine and Tobacco Research. 2025;27(7):1294-1300. doi:10.1093/ntr/ntaf005
BibTeX
@article{Yammine2025,
author = {Yammine, Luba and de Dios, Constanza and Suchting, Robert and Green, Charles E and Nielsen, David A and Walss-Bass, Consuelo and Schmitz, Joy M},
title = {Exploring Predictors of Treatment Response to GLP-1 Receptor Agonists for Smoking Cessation},
journal = {Nicotine and Tobacco Research},
year = {2025},
volume = {27},
number = {7},
pages = {1294--1300},
doi = {10.1093/ntr/ntaf005}
}
EUVIMED